Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
NCT04957485 · SIGA Technologies
Primary completion dateRecorded edit
− Previous value
2026-01-01
+ Updated value
2027-01-01
SIGA
SIGA Technologies
Company identity has not yet been verified
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
4Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246NCT00907803 | SIGA Technologies | Phase 2 | Completed | 2010-01Actual |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatNCT02474589 | SIGA Technologies | Phase 3 | Completed | 2016-08-24Actual |
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 | SIGA Technologies | Phase 2 | Active not recruiting | 2027-01-01Estimated |
| Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysNCT04971109 | SIGA Technologies | Phase 3 | Completed | 2023-05-12Actual |